Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets

Plasma cells (PCs) are essentially characterized by the co-expression of CD138 and CD38, which allows their identification in flow cytometry in bone marrow (BM), peripheral blood, or cell suspensions from tissues. These terminally differentiated B-cells may lose the expression of surface CD19 and th...

Full description

Bibliographic Details
Main Authors:	Robillard, Nelly, Wuillème, Soraya, Moreau, Philippe, Béné, Marie C.
Format:	Online
Language:	English
Published:	Frontiers Media S.A. 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978250/

id	pubmed-3978250
recordtype	oai_dc
spelling	pubmed-39782502014-04-17 Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets Robillard, Nelly Wuillème, Soraya Moreau, Philippe Béné, Marie C. Immunology Plasma cells (PCs) are essentially characterized by the co-expression of CD138 and CD38, which allows their identification in flow cytometry in bone marrow (BM), peripheral blood, or cell suspensions from tissues. These terminally differentiated B-cells may lose the expression of surface CD19 and that of CD20 while retaining CD27. When malignant, they can gain a number of other markers such as CD28, CD33, CD56, or CD117 and lose CD27. Moreover, since each PC is only able to produce a single type of immunoglobulins (Igs), they display isotypic restriction and clonal malignant PCs can be further characterized by their homogeneous expression of either kappa or lambda light chains. In multiple myeloma (MM), such PC clones produce the Ig identified in plasma as an abnormal peak. In the BM where they essentially accumulate, these PCs may however display various immunophenotypes. The latter were explored in a two-way approach. Firstly, the various subsets delineated by the selective or common expression of CD19 together with combined CD56/CD28 were explored in normal and MM BM. Then, other aberrant markers’ expression was investigated, i.e., CD20, CD27, CD33, CD56, CD117. These data were compared to literature information. They underline the vast heterogeneity of MM PCs possibly accounting for the various answers to therapy of MM patients. Frontiers Media S.A. 2014-03-31 /pmc/articles/PMC3978250/ /pubmed/24744760 http://dx.doi.org/10.3389/fimmu.2014.00137 Text en Copyright © 2014 Robillard, Wuillème, Moreau and Béné. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Robillard, Nelly Wuillème, Soraya Moreau, Philippe Béné, Marie C.
spellingShingle	Robillard, Nelly Wuillème, Soraya Moreau, Philippe Béné, Marie C. Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets
author_facet	Robillard, Nelly Wuillème, Soraya Moreau, Philippe Béné, Marie C.
author_sort	Robillard, Nelly
title	Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets
title_short	Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets
title_full	Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets
title_fullStr	Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets
title_full_unstemmed	Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets
title_sort	immunophenotype of normal and myelomatous plasma-cell subsets
description	Plasma cells (PCs) are essentially characterized by the co-expression of CD138 and CD38, which allows their identification in flow cytometry in bone marrow (BM), peripheral blood, or cell suspensions from tissues. These terminally differentiated B-cells may lose the expression of surface CD19 and that of CD20 while retaining CD27. When malignant, they can gain a number of other markers such as CD28, CD33, CD56, or CD117 and lose CD27. Moreover, since each PC is only able to produce a single type of immunoglobulins (Igs), they display isotypic restriction and clonal malignant PCs can be further characterized by their homogeneous expression of either kappa or lambda light chains. In multiple myeloma (MM), such PC clones produce the Ig identified in plasma as an abnormal peak. In the BM where they essentially accumulate, these PCs may however display various immunophenotypes. The latter were explored in a two-way approach. Firstly, the various subsets delineated by the selective or common expression of CD19 together with combined CD56/CD28 were explored in normal and MM BM. Then, other aberrant markers’ expression was investigated, i.e., CD20, CD27, CD33, CD56, CD117. These data were compared to literature information. They underline the vast heterogeneity of MM PCs possibly accounting for the various answers to therapy of MM patients.
publisher	Frontiers Media S.A.
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978250/
_version_	1612075062502883328

Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets

Similar Items